



FINANCIAL TEAR SHEET


Corporate Profile

Jounce Therapeutics is a clinical stage immuno-oncology company dedicated to transforming the treatment of cancer. The company is discovering and developing novel cancer immunotherapies designed to harness the immune system to attack tumors and provide long-lasting benefits to patients. Jounce integrates translational science insights, including identification of related biomarkers designed to match the right immunotherapy to the right patients. The company is advancing programs that leverage contributions from its world-class founders, as well as knowledge acquired from Jounce’s Translational Science Platform, to create a sustainable “discovery to human proof-of-concept” product engine with the potential to drive significantly more long-lasting responses to treatment.

Stock Information

JNCE (COMMON STOCK)	
Exchange	NASDAQ GS (US Dollar)
Price	\$14.91
Change (%)	▼ 0.13 (0.86%)
Volume	93,053
52 Week Low	\$11.05
Market Cap	\$484,976,260
Rolling EPS	-0.17
PE Ratio	0
Shares Outstanding	32,245,762

Data as of 11/21/17 4:00 p.m. ET



Recent Headlines & Events

11/13/17 - 6:30 a.m.
Jounce Therapeutics Reports Third Quarter
2017 Financial Results

11/09/17 - 8:01 a.m.
Jounce Therapeutics to Present at the Stifel
2017 Healthcare Conference

11/08/17 - 8:01 a.m.
Jounce Therapeutics to Announce Third
Quarter 2017 Financial Results and Host
Conference Call on Monday, November 13,
2017

There are currently no events scheduled.

SEC Filings

FILING DATE	FORM
11/13/17	10-Q
11/13/17	8-K
10/23/17	4
10/23/17	3

Data provided by NASDAQ. Stock information is delayed a minimum of 15 minutes.